Cargando…
Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease
Alcoholic liver disease (ALD) is linked to a broad spectrum of diseases, including diabetes, hypertension, atherosclerosis, and even liver carcinoma. The ALD spectrum includes alcoholic fatty liver disease (AFLD), alcoholic hepatitis, and cirrhosis. Most recently, some reports demonstrated that the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316215/ https://www.ncbi.nlm.nih.gov/pubmed/35877448 http://dx.doi.org/10.3390/cimb44070224 |
_version_ | 1784754755292102656 |
---|---|
author | Oh, Ki-Kwang Choi, Ye-Rin Gupta, Haripriya Ganesan, Raja Sharma, Satya Priya Won, Sung-Min Jeong, Jin-Ju Lee, Su-Been Cha, Min-Gi Kwon, Goo-Hyun Kim, Dong-Joon Suk, Ki-Tae |
author_facet | Oh, Ki-Kwang Choi, Ye-Rin Gupta, Haripriya Ganesan, Raja Sharma, Satya Priya Won, Sung-Min Jeong, Jin-Ju Lee, Su-Been Cha, Min-Gi Kwon, Goo-Hyun Kim, Dong-Joon Suk, Ki-Tae |
author_sort | Oh, Ki-Kwang |
collection | PubMed |
description | Alcoholic liver disease (ALD) is linked to a broad spectrum of diseases, including diabetes, hypertension, atherosclerosis, and even liver carcinoma. The ALD spectrum includes alcoholic fatty liver disease (AFLD), alcoholic hepatitis, and cirrhosis. Most recently, some reports demonstrated that the pathogenesis of ALD is strongly associated with metabolites of human microbiota. AFLD was the onset of disease among ALDs, the initial cause of which is alcohol consumption. Thus, we analyzed the significant metabolites of microbiota against AFLD via the network pharmacology concept. The metabolites from microbiota were retrieved by the gutMGene database; sequentially, AFLD targets were identified by public databases (DisGeNET, OMIM). The final targets were utilized for protein–protein interaction (PPI) networks and signaling pathway analyses. Then, we performed a molecular docking test (MDT) to verify the affinity between metabolite(s) and target(s) utilizing the Autodock 1.5.6 tool. From a holistic viewpoint, we integrated the relationships of microbiota-signaling pathways-targets-metabolites (MSTM) using the R Package. We identified the uppermost six key targets (TLR4, RELA, IL6, PPARG, COX-2, and CYP1A2) against AFLD. The PPI network analysis revealed that TLR4, RELA, IL6, PPARG, and COX-2 had equivalent degrees of value (4); however, CYP1A2 had no associations with the other targets. The bubble chart showed that the PI3K-Akt signaling pathway in nine signaling pathways might be the most significant mechanism with antagonistic functions in the treatment of AFLD. The MDT confirmed that Icaritin is a promising agent to bind stably to RELA (known as NF-Κb). In parallel, Bacterium MRG-PMF-1, the PI3K-Akt signaling pathway, RELA, and Icaritin were the most significant components against AFLD in MSTM networks. In conclusion, we showed that the Icaritin–RELA complex on the PI3K-Akt signaling pathway by bacterial MRG-PMF-1 might have promising therapeutic effects against AFLD, providing crucial evidence for further research. |
format | Online Article Text |
id | pubmed-9316215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93162152022-07-27 Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease Oh, Ki-Kwang Choi, Ye-Rin Gupta, Haripriya Ganesan, Raja Sharma, Satya Priya Won, Sung-Min Jeong, Jin-Ju Lee, Su-Been Cha, Min-Gi Kwon, Goo-Hyun Kim, Dong-Joon Suk, Ki-Tae Curr Issues Mol Biol Hypothesis Alcoholic liver disease (ALD) is linked to a broad spectrum of diseases, including diabetes, hypertension, atherosclerosis, and even liver carcinoma. The ALD spectrum includes alcoholic fatty liver disease (AFLD), alcoholic hepatitis, and cirrhosis. Most recently, some reports demonstrated that the pathogenesis of ALD is strongly associated with metabolites of human microbiota. AFLD was the onset of disease among ALDs, the initial cause of which is alcohol consumption. Thus, we analyzed the significant metabolites of microbiota against AFLD via the network pharmacology concept. The metabolites from microbiota were retrieved by the gutMGene database; sequentially, AFLD targets were identified by public databases (DisGeNET, OMIM). The final targets were utilized for protein–protein interaction (PPI) networks and signaling pathway analyses. Then, we performed a molecular docking test (MDT) to verify the affinity between metabolite(s) and target(s) utilizing the Autodock 1.5.6 tool. From a holistic viewpoint, we integrated the relationships of microbiota-signaling pathways-targets-metabolites (MSTM) using the R Package. We identified the uppermost six key targets (TLR4, RELA, IL6, PPARG, COX-2, and CYP1A2) against AFLD. The PPI network analysis revealed that TLR4, RELA, IL6, PPARG, and COX-2 had equivalent degrees of value (4); however, CYP1A2 had no associations with the other targets. The bubble chart showed that the PI3K-Akt signaling pathway in nine signaling pathways might be the most significant mechanism with antagonistic functions in the treatment of AFLD. The MDT confirmed that Icaritin is a promising agent to bind stably to RELA (known as NF-Κb). In parallel, Bacterium MRG-PMF-1, the PI3K-Akt signaling pathway, RELA, and Icaritin were the most significant components against AFLD in MSTM networks. In conclusion, we showed that the Icaritin–RELA complex on the PI3K-Akt signaling pathway by bacterial MRG-PMF-1 might have promising therapeutic effects against AFLD, providing crucial evidence for further research. MDPI 2022-07-19 /pmc/articles/PMC9316215/ /pubmed/35877448 http://dx.doi.org/10.3390/cimb44070224 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Hypothesis Oh, Ki-Kwang Choi, Ye-Rin Gupta, Haripriya Ganesan, Raja Sharma, Satya Priya Won, Sung-Min Jeong, Jin-Ju Lee, Su-Been Cha, Min-Gi Kwon, Goo-Hyun Kim, Dong-Joon Suk, Ki-Tae Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease |
title | Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease |
title_full | Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease |
title_fullStr | Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease |
title_full_unstemmed | Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease |
title_short | Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease |
title_sort | identification of gut microbiome metabolites via network pharmacology analysis in treating alcoholic liver disease |
topic | Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316215/ https://www.ncbi.nlm.nih.gov/pubmed/35877448 http://dx.doi.org/10.3390/cimb44070224 |
work_keys_str_mv | AT ohkikwang identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT choiyerin identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT guptaharipriya identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT ganesanraja identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT sharmasatyapriya identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT wonsungmin identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT jeongjinju identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT leesubeen identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT chamingi identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT kwongoohyun identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT kimdongjoon identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease AT sukkitae identificationofgutmicrobiomemetabolitesvianetworkpharmacologyanalysisintreatingalcoholicliverdisease |